Evidence of Haloperidol Absorption After Topical Administration

Topical Haloperidol: Evidence of Absorption After Topical Administration

This will be a blinded study to compare the absorption of topical haloperidol with placebo

Inclusion Criteria

• Age: patient must be 18 years or older and less than 70 years of age.
• Provision of informed consent
• No previous adverse reaction to haloperidol
• No current use of haloperidol
• Good health
• No alcohol within 24 hours of the study
• No significant cardiovascular, gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.
• Normal neurologic exam

Exclusionary Criteria

• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
• Recent cerebral trauma
• Study will exclude women who are pregnant and/or nursing
• Women who are of child bearing potential must have a negative urine pregnancy test.
• History of seizures
• Taking medications that can interact with haloperidol
• Subjects with significant cardiovascular (cardiac conduction deficits), gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.